Fig. 4. Cisplatin administration impairs the mitochondrial GSH-mediated antioxidant system in the kidney.

Idh2^‒/‒ mice and wild-type (Idh2^+/+) littermates were intraperitoneally injected with either cisplatin (C, 20 mg/kg B.W.) or 0.9% saline (vehicle, V) once. Some mice were treated with Mito-T (M, 0.7 mg/kg B.W.) daily, beginning 7 days before cisplatin injection and continuing until experiments were completed. Kidneys were harvested 3 days after cisplatin injection. a–c Oxidized GSH (GSSG) levels (a), reduced GSH levels (b), and the GSSG/tGSH ratio (c) were determined in mitochondrial fractions. d, e GSH-Px (d) and GR (e) activities were measured in mitochondrial fractions. Results are expressed as means ± SE (n = 4 per group). *p < 0.05 vs. respective V; ^#p < 0.05 vs. respective C; ^§p < 0.05 vs. V in Idh2^+/+; ^†p < 0.05 vs. C in Idh2^+/+